Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
This marks the first FDA approval of an AI-based brain disorder analysis solution from Korea
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Establishing Asymchem’s first manufacturing footprint in Europe
For use with Hamamatsu Images acquired with the NanoZoomer S360MD slide scanner
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The collaboration aims to bolster healthcare entrepreneurship
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
